Literature DB >> 24468651

Immune modulation in humans: implications for type 1 diabetes mellitus.

Bart O Roep1, Timothy I M Tree2.   

Abstract

Type 1 diabetes mellitus (T1DM) is the result of autoimmune destruction of pancreatic β cells in genetically predisposed individuals with impaired immune regulation. The insufficiency in the modulation of immune attacks on the β cells might be partly due to genetic causes; indeed, several of the genetic variants that predispose individuals to T1DM have functional features of impaired immune regulation. Whilst defects in immune regulation in patients with T1DM have been identified, many patients seem to have immune regulatory capacities that are indistinguishable from those of healthy individuals. Insight into the regulation of islet autoimmunity might enable us to restore immune imbalances with therapeutic interventions. In this Review, we discuss the current knowledge on immune regulation and dysfunction in humans that is the basis of tissue-specific immune regulation as an alternative to generalized immune suppression.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24468651     DOI： 10.1038/nrendo.2014.2

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  146 in total

1.  Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.

Authors:  Stephen E Gitelman; Peter A Gottlieb; Mark R Rigby; Eric I Felner; Steven M Willi; Lynda K Fisher; Antoinette Moran; Michael Gottschalk; Wayne V Moore; Ashley Pinckney; Lynette Keyes-Elstein; Sudeepta Aggarwal; Deborah Phippard; Peter H Sayre; Linna Ding; Jeffrey A Bluestone; Mario R Ehlers
Journal:  Lancet Diabetes Endocrinol       Date:  2013-08-28       Impact factor: 32.069

Review 2.  Anti-TNF treatment in rheumatoid arthritis.

Authors:  Janina Geiler; Maya Buch; Michael F McDermott
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 3.  A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop.

Authors:  Timothy I M Tree; Bart O Roep; Mark Peakman
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

Review 4.  Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns.

Authors:  Makoto Miyara; Shimon Sakaguchi
Journal:  Immunol Cell Biol       Date:  2011-02-08       Impact factor: 5.126

Review 5.  How regulatory T cells work.

Authors:  Dario A A Vignali; Lauren W Collison; Creg J Workman
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

6.  The effect of the MHC locus on autoantibodies in type 1 diabetes.

Authors:  H-Q Qu; C Polychronakos
Journal:  J Med Genet       Date:  2009-05-07       Impact factor: 6.318

7.  Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.

Authors:  Deepen Patel; Peter Couroux; Pascal Hickey; Anne Marie Salapatek; Paul Laidler; Mark Larché; Roderick P Hafner
Journal:  J Allergy Clin Immunol       Date:  2012-09-13       Impact factor: 10.793

Review 8.  Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans.

Authors:  Maria-Grazia Roncarolo; Manuela Battaglia
Journal:  Nat Rev Immunol       Date:  2007-08       Impact factor: 53.106

9.  Evidence that HLA class I and II associations with type 1 diabetes, autoantibodies to GAD and autoantibodies to IA-2, are distinct.

Authors:  Joanna M M Howson; Helen Stevens; Deborah J Smyth; Neil M Walker; Kyla A Chandler; Polly J Bingley; John A Todd
Journal:  Diabetes       Date:  2011-08-10       Impact factor: 9.461

10.  C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study.

Authors:  Raffaella Buzzetti; Simona Cernea; Antonio Petrone; Marco Capizzi; Marialuisa Spoletini; Simona Zampetti; Chiara Guglielmi; Chiara Venditti; Paolo Pozzilli
Journal:  Diabetes       Date:  2011-09-06       Impact factor: 9.461
View more
  55 in total

1.  Primary prevention for type 1 diabetes mellitus?

Authors:  Bart O Roep
Journal:  Nat Rev Endocrinol       Date:  2015-06-16       Impact factor: 43.330

2.  SET7/9 Enzyme Regulates Cytokine-induced Expression of Inducible Nitric-oxide Synthase through Methylation of Lysine 4 at Histone 3 in the Islet β Cell.

Authors:  Kyoko Fujimaki; Takeshi Ogihara; David L Morris; Hisanobu Oda; Hitoshi Iida; Yoshio Fujitani; Raghavendra G Mirmira; Carmella Evans-Molina; Hirotaka Watada
Journal:  J Biol Chem       Date:  2015-05-20       Impact factor: 5.157

Review 3.  Understanding the complexity and malleability of T-cell recognition.

Authors:  John J Miles; James McCluskey; Jamie Rossjohn; Stephanie Gras
Journal:  Immunol Cell Biol       Date:  2015-01-13       Impact factor: 5.126

Review 4.  Current stem cell based therapies in diabetes.

Authors:  Meredith A Lilly; Meghan F Davis; Josh E Fabie; Elizabeth B Terhune; G Ian Gallicano
Journal:  Am J Stem Cells       Date:  2016-10-20

Review 5.  Galectin-3 in autoimmunity and autoimmune diseases.

Authors:  Felipe L de Oliveira; Mariele Gatto; Nicola Bassi; Roberto Luisetto; Anna Ghirardello; Leonardo Punzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2015-07-03

6.  Dextran Sulfate Protects Pancreatic β-Cells, Reduces Autoimmunity, and Ameliorates Type 1 Diabetes.

Authors:  Geming Lu; Francisco Rausell-Palamos; Jiamin Zhang; Zihan Zheng; Tuo Zhang; Shelley Valle; Carolina Rosselot; Cecilia Berrouet; Patricia Conde; Matthew P Spindler; John G Graham; Dirk Homann; Adolfo Garcia-Ocaña
Journal:  Diabetes       Date:  2020-05-07       Impact factor: 9.461

7.  Cross-talks between microRNAs and mRNAs in pancreatic tissues of streptozotocin-induced type 1 diabetic mice.

Authors:  Caiming Tian; Xiaoxi Ouyang; Qing Lv; Yaou Zhang; Weidong Xie
Journal:  Biomed Rep       Date:  2015-02-12

8.  Of Mice and Men: Protective and Pathogenic Immune Responses to West Nile virus Infection.

Authors:  Derek Trobaugh; Sharone Green
Journal:  Curr Trop Med Rep       Date:  2015-03-01

9.  Downregulation of cathepsin G reduces the activation of CD4+ T cells in murine autoimmune diabetes.

Authors:  Fang Zou; Xiaoyang Lai; Jing Li; Shuihong Lei; Lei Hu
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

10.  Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.

Authors:  Kurt J Griffin; Paul A Thompson; Michael Gottschalk; Jennifer H Kyllo; Alex Rabinovitch
Journal:  Lancet Diabetes Endocrinol       Date:  2014-07-02       Impact factor: 32.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.